Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 570 participants.

Also called NCT05752916

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 570 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05752916
Other papers using this trial's data
  • Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial JAMA, 2026-04-07 DOI, PubMed 41642827, PMC12878635 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05752916. Randomized; single masking; primary purpose treatment. Start 2023-06-02 (actual); primary completion 2025-10-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
Acronym
OPTION
Condition
Acute Ischemic Stroke
Intervention (Drug)
rhTNK-tPA
Intervention (Drug)
Antiplatelet Agents
Lead sponsor
Xuanwu Hospital, Beijing (class: other)
Collaborator
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (class: industry)
Collaborator
Beijing Hospitals Authority (class: not stated)

Record details

Record id
cardio:ct-nct05752916
Content hash
b16c717b2c704e7d342b74578c43c73f1be92bc4de293800abcb4dd9b0814f2d